Status Quo

For a patient, a cancer diagnosis often means a serious change in his or her life. In addition to the uncertainty as to how the disease will progress, the treatment is extremely stressful. This makes it all the more important to develop new methods through research that both personalize the therapy and make the treatment more pleasant for the patient. With the help of the device developed by us, an optimized monitoring results, with which the healing process of cancer patients is supervised clearly more precisely. We achieve this with the help of the Heat Shock Protein HSP70. Compared to healthy people, cancer patients have a higher concentration of HSP70. At the Chair of Experimental Radiooncology and Radiobiology of Prof. Multhoff (TUM), antibodies are being researched that specifically bind to the HSP70 protein. In the further course of the process, radiation in the visible range is emitted, which we measure with extremely sensitive silicon photomultipliers. These components are even able to detect single photons. The intensity of the radiation is therefore a measure of the amount of heat shock proteins found in the blood. This size correlates to a certain extent with the number of cancer cells in the body. According to the current state of the art, there is no automated solution for the measurement of HSP70 concentrations. Our approach is therefore to use repeated blood analyses of the patient to monitor the effectiveness of the cancer treatment as well as the exact healing process of the affected person.